Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis.

This study is a network meta-analysis assessing the histological efficacy of various pharmacological agents for patients with biopsy-proven compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis, specifically stage F4c. The analysis included a total sample size of 3266 patients. The setting of the underlying studies was not reported. The primary objective was to determine which interventions were most effective at achieving fibrosis regression of at least one stage without worsening of MASH activity. Secondary outcomes included the resolution of MASH.

The primary outcome analysis revealed that efruxifermin was the only intervention significantly superior to placebo regarding fibrosis regression of at least one stage without MASH worsening. The ranking probability for this outcome, measured by SUCRA, was 77.44 for efruxifermin. Other interventions, including the combination of cilofexor and firsocostat (SUCRA 72.38) and aldafermin (SUCRA 71.27), were also ranked highly but were not statistically superior to placebo for this specific primary endpoint in the same manner.

Regarding the secondary outcome of MASH resolution, three interventions demonstrated significant superiority over placebo. Efruxifermin achieved the highest ranking probability with a SUCRA of 81.38. The combination of semaglutide, cilofexor, and firsocostat followed with a SUCRA of 74.07, and semaglutide alone had a SUCRA of 63.88. These findings indicate that multiple therapeutic strategies may offer benefits for resolving MASH activity in this population.

Safety and tolerability findings were not reported in the available data. Similarly, specific rates of adverse events, serious adverse events, discontinuations, and overall tolerability profiles were not provided. Consequently, a comprehensive assessment of the risk-benefit profile for these agents cannot be derived from this specific analysis. The absolute numbers for patient outcomes were also not reported, limiting the ability to calculate specific event rates or absolute risk reductions.

The study design is a network meta-analysis, which allows for the comparison of multiple interventions simultaneously, even if they were not directly compared in the same randomized controlled trial. However, the limitations of the included studies, potential biases, and the certainty of the evidence were not reported. The funding sources and conflicts of interest for the analysis were also not disclosed. These omissions prevent a full evaluation of the robustness of the conclusions.

These data may have implications for the design of future clinical trials in the field of MASH cirrhosis treatment. While efruxifermin emerges as a promising candidate for fibrosis regression, the lack of reported safety data and absolute numbers necessitates caution in clinical interpretation. The results highlight the need for further research to confirm these findings and to establish the safety profiles of these novel agents. Questions remain regarding the long-term tolerability and the specific mechanisms by which these agents achieve histological improvement.

In summary, this network meta-analysis suggests that efruxifermin is the most effective agent for fibrosis regression without MASH worsening among those evaluated. However, the absence of reported safety data, absolute numbers, and methodological certainty notes limits the immediate clinical applicability. Clinicians should interpret these results as preliminary evidence that may inform future trial designs rather than definitive guidance for current practice, pending further data on safety and long-term outcomes.